The New Humphrey Field Analyzer 3 from ZEISS

Article

The New HFA3 offers gold-standard perimetry performance with technological advances – such as automated trial lens correction with liquid lens technology – that are designed to save time and reduce errors.

The New Humphrey Field Analyzer 3 from ZEISS

Setting a New Standard for Efficient Visual Field Testing


The new Humphrey Field Analyzer 3 (HFA3) from ZEISS, is the next generation in visual field testing and analysis. The HFA3 is designed to accelerate clinic flow while delivering the same gold-standard testing strategies and test patterns.

The New HFA3 provides a streamlined and faster workflow with an array of new features designed to:

  • Reduce setup time with a single trial lens. Using liquid pressure, the new Liquid Trial Lens™ instantly delivers each patient’s refractive correction with the touch of a button.*

  • Save time with an intuitive new SmartTouch™ interface, which reduces the number of steps required for the technician to start a perimetry exam.

  • Accelerate clinic flow with equipment that can be learned quickly and operated easily.

  • Improve confidence in test results with RelEYE™, which allows doctors to instantly review the patient’s eye position, at any stimulus point. RelEYE data is available on the instrument and when reviewing test results with FORUM® Glaucoma Workplace.

  • Simplify test administration, with an easy-to-use kinetic graphical user interface with a full 180-degree field of view.

 

Find out more: www.zeiss.com/HFA3Contact us: www.meditec.zeiss.com/contacts

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.